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AIMS AND BACKGROUND: In recent years, the number of oral anticancer drugs used in
clinical practice has rapidly increased. The Italian Society of Medical Oncology 
(AIOM) conducted a survey to describe the impact of the use of oral anticancer
drugs on the daily activity of Italian oncology practices.
METHODS AND STUDY DESIGN: A survey questionnaire was distributed to the
coordinators of the regional sections of AIOM. A 6-month period was considered,
from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative
aspects of the use of oral anticancer drugs; (2) practical aspects in the
management of patients treated with these drugs; (3) issues related to treatment 
costs and reimbursement procedures.
RESULTS: Thirty-six questionnaires were received from institutions distributed
throughout the Italian territory. Oral anticancer drugs (both chemotherapy and
molecularly targeted agents) accounted for a significant proportion (17%) of
prescribed treatments. Among the responding institutions, there were different
dispensation procedures of oral drugs to patients: drugs were dispensed by the
pharmacist (57%) or directly by the medical oncologist (23%) or nurse (20%). The 
medical oncologist played a major role in the communication with patients (73%
alone and a further 24% in cooperation with other professional figures) and was
the point of reference in the event of side effects in 97% of cases. In most
cases, the reimbursement of drug costs was separated ("File F" procedure) from
the flat fare received by the hospital for outpatient visits or day-hospital
access.
CONCLUSIONS: Optimal organization of oral anticancer treatment warrants the
cooperation and integration of multiple professional figures. At least three
figures are involved in patient management in the hospital: the medical
oncologist, the nurse, and the hospital pharmacist. Oral anticancer treatments
are associated with specific reimbursement issues: in the majority of cases, the 
cost of the drug is reimbursed separately from the cost of patient access.
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